Suppr超能文献

B 细胞和 T 细胞基因重排研究在评估淋巴增殖性疾病中的作用和局限性。

The utility and limitations of B- and T-cell gene rearrangement studies in evaluating lymphoproliferative disorders.

机构信息

Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.

Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

出版信息

Pathology. 2021 Feb;53(2):157-165. doi: 10.1016/j.pathol.2020.09.024. Epub 2020 Dec 25.

Abstract

A hallmark of lymphoid malignancies is the presence of a monoclonal lymphocyte population. Monoclonality of B- and T-cell populations can be established through immunoglobulin (IG) or T-cell receptor (TCR) gene rearrangement analysis, respectively. The biological rationale of IG and TCR gene rearrangement analysis is that due to the extensive combinatorial repertoire made possible by V(D)J recombination in lymphocytes, it is unlikely that any substantive lymphocyte population would share the same IG or TCR gene rearrangement pattern unless there is an underlying neoplastic or reactive origin. Modern IG and TCR gene rearrangement analysis is typically performed by polymerase chain reaction (PCR) using commercially available primer sets followed by gel capillary electrophoresis. This process is highly sensitive in the detection of nearly all lymphoid malignancies. Several pitfalls and limitations, both biological and technical, apply to IG/TCR gene rearrangement analysis, but these can be minimised with high quality controls, performance of assays in duplicate, and adherence to strict criteria for interpreting and reporting results. Next generation sequencing (NGS) will likely replace PCR based methods of IG/TCR gene rearrangement analysis but is not yet widespread due to the absence of standardised protocols and multicentre validation.

摘要

淋巴恶性肿瘤的一个标志是存在单克隆淋巴细胞群。B 细胞和 T 细胞群体的单克隆性可以分别通过免疫球蛋白 (IG) 或 T 细胞受体 (TCR) 基因重排分析来确定。IG 和 TCR 基因重排分析的生物学原理是,由于淋巴细胞中的 V(D)J 重组使组合库广泛,除非存在潜在的肿瘤或反应性起源,否则任何实质性的淋巴细胞群体都不太可能具有相同的 IG 或 TCR 基因重排模式。现代 IG 和 TCR 基因重排分析通常通过聚合酶链反应 (PCR) 使用市售引物对进行,然后进行凝胶毛细管电泳。该过程在检测几乎所有淋巴恶性肿瘤方面具有高度敏感性。IG/TCR 基因重排分析存在一些生物学和技术上的陷阱和限制,但通过高质量的控制、双重检测、以及严格的解释和报告结果标准,可以将这些限制最小化。下一代测序 (NGS) 可能会取代基于 PCR 的 IG/TCR 基因重排分析方法,但由于缺乏标准化协议和多中心验证,尚未广泛应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验